MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc. (INKT) priced its initial public offering on Oct 15, 2021 at $12.00 per share, within its $12.00–$14.00 range, raising $40M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $391M. Ropes & Gray advised the company and Covington & Burling advised the underwriters.

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. These cells combine durable memory responses with the rapid cell-killing features of natural killer cells.

Status

IPO

Ticker

INKT

Exchange

Nasdaq Global Market

Priced

Oct 15, 2021

IPO price

$12.00

Price range

$12.00–$14.00

Raised

$40M

Market cap at IPO price

$391M

First filed

Sep 14, 2021

Company counsel

Ropes & Gray

Underwriters' counsel

Covington & Burling

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.